Tom Cavanuagh is Executive Vice President and Worldwide Chairman, Innovative Medicine at Johnson & Johnson, the world’s largest healthcare company. He is a member of J&J’s Executive Committee and leads the Innovative Medicine Group Operating Committee.
Tom oversees a business of more than $60 billion in annual revenue, setting the global strategy for a portfolio and pipeline of transformational medicines to prevent, treat and cure complex diseases including cancer, immune-related disorders, serious mental illness, and cardiovascular diseases.
Since joining Johnson & Johnson in 2017, Tom has held senior leadership positions in Oncology, Immunology and Global Commercial Strategy. Most recently, he led the Company’s largest commercial region, driving growth, strengthening execution, advancing capabilities and developing talent across the organization. Prior to joining Johnson & Johnson, Tom spent nearly 15 years at Celgene in global product development, global medical affairs, global and regional marketing, and general management roles in Spain and the U.S. He began his career as a production chemist and pharmacy technician.
Tom received a bachelor’s degree in chemistry from North Carolina State University and serves on the Board of Directors of the Biotechnology Innovation Organization (BIO).
Throughout his career, Tom has been recognized for his authentic leadership, ability to unite teams around a shared purpose, and commitment to improving outcomes for patients worldwide.
